224 related articles for article (PubMed ID: 24934059)
1. [Pay more attention to hepatic encephalopathy].
Labenz J
MMW Fortschr Med; 2014 Feb; 156(2):60-1. PubMed ID: 24934059
[No Abstract] [Full Text] [Related]
2. [Hepatic encephalopathy. Rifaximin opens new perspectives].
MMW Fortschr Med; 2014 Jul; 156(13):78-9. PubMed ID: 25318235
[No Abstract] [Full Text] [Related]
3. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy.
Sidhu SS; Goyal O; Parker RA; Kishore H; Sood A
Liver Int; 2016 Mar; 36(3):378-85. PubMed ID: 26201713
[TBL] [Abstract][Full Text] [Related]
4. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
5. Minimal hepatic encephalopathy in cirrhosis- how long to treat?
Goyal O; Sidhu SS; Kishore H
Ann Hepatol; 2017 Jan-Feb 2017; 16(1):115-122. PubMed ID: 28051800
[TBL] [Abstract][Full Text] [Related]
6. [Intestine specific broad spectrum antibiotic. Rifaximin: therapy option in hepatic encephalopathy].
MMW Fortschr Med; 2014 Feb; 156(3):64-5. PubMed ID: 24938070
[No Abstract] [Full Text] [Related]
7. Diagnostic Performance of the ICD-10 Code K76.82 for Hepatic Encephalopathy in Patients With Cirrhosis.
Ozturk NB; Jamil LH; Tapper EB
Am J Gastroenterol; 2024 Feb; 119(2):364-366. PubMed ID: 37830544
[TBL] [Abstract][Full Text] [Related]
8. Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy.
Hayakawa Y; Tamaki N; Nakanishi H; Kurosaki M; Tanaka Y; Inada K; Ishido S; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Kaneko S; Yasui Y; Takahashi Y; Tsuchiya K; Okamoto R; Izumi N
Intern Med; 2023 Apr; 62(7):973-978. PubMed ID: 36070941
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
Irimia R; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
[TBL] [Abstract][Full Text] [Related]
10. Rifaximin for the treatment of hepatic encephalopathy.
Mantry PS; Munsaf S
Transplant Proc; 2010 Dec; 42(10):4543-7. PubMed ID: 21168733
[TBL] [Abstract][Full Text] [Related]
11. Durability of rifaximin response in hepatic encephalopathy.
Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
[TBL] [Abstract][Full Text] [Related]
12. Rifaximin treatment in hepatic encephalopathy.
Bass NM; Mullen KD; Sanyal A; Poordad F; Neff G; Leevy CB; Sigal S; Sheikh MY; Beavers K; Frederick T; Teperman L; Hillebrand D; Huang S; Merchant K; Shaw A; Bortey E; Forbes WP
N Engl J Med; 2010 Mar; 362(12):1071-81. PubMed ID: 20335583
[TBL] [Abstract][Full Text] [Related]
13. Factors affecting compliance and persistence with treatment for hepatic encephalopathy.
Neff G
Pharmacotherapy; 2010 May; 30(5 Pt 2):22S-7S. PubMed ID: 20412037
[TBL] [Abstract][Full Text] [Related]
14. Optimal treatment of hepatic encephalopathy.
Waghray A; Waghray N; Kanna S; Mullen K
Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
[TBL] [Abstract][Full Text] [Related]
15. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose.
Sharma P; Sharma BC; Agrawal A; Sarin SK
J Gastroenterol Hepatol; 2012 Aug; 27(8):1329-35. PubMed ID: 22606978
[TBL] [Abstract][Full Text] [Related]
16. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy.
Leevy CB; Phillips JA
Dig Dis Sci; 2007 Mar; 52(3):737-41. PubMed ID: 17245628
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care.
Bohra A; Worland T; Hui S; Terbah R; Farrell A; Robertson M
World J Gastroenterol; 2020 May; 26(18):2221-2231. PubMed ID: 32476788
[TBL] [Abstract][Full Text] [Related]
18. Lactulose a day keeps encephalopathy at bay.
Klinken E; MacQuillan G
J Gastroenterol Hepatol; 2011 Jun; 26(6):939-40. PubMed ID: 21564285
[No Abstract] [Full Text] [Related]
19. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
Huang E; Esrailian E; Spiegel BM
Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis.
Bajaj JS; Pinkerton SD; Sanyal AJ; Heuman DM
Hepatology; 2012 Apr; 55(4):1164-71. PubMed ID: 22135042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
